This site is for informational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult your healthcare provider.
A Study to Learn More About How Safe Darolutamide is Under Real-world Conditions in Participants With Metastatic Hormone-Sensitive Prostate Cancer | MicrobiomeTrials
← Back to trials NCT06010914
A Study to Learn More About How Safe Darolutamide is Under Real-world Conditions in Participants With Metastatic Hormone-Sensitive Prostate Cancer Recruiting OBSERVATIONAL
Read the full scientific description See full eligibility requirements Trial Details Start: 2023-10-09Est. Completion: 2026-03-16
Enrollment target: 100 participantsLocations Many Locations, Multiple Locations, Japan Other microbiome trials you might be interested in Metastatic Hormone-sensitive Prostate Cancer
This is a phase III, randomized, open-label, multi-center study to assess the efficacy of treatment intensification with…
Bayonne, France Est. completion Mar 31, 2030
Recurrent Prostate Adenocarcinoma Stage IVB Prostate Cancer AJCC v8 Castration-Sensitive Prostate Cancer Metastatic Hormone-sensitive Prostate Cancer (mHSPC) Prostate Cancer
Prostate Adenocarcinoma
Adenocarcinoma of the Prostate
Localized Prostate Carcinoma
Metastatic Prostate Cancer
Metastatic Prostate Adenocarcinoma
Advanced Prostate Cancer
Advanced Prostate Adenocarcinoma
This phase II trial tests leuprolide acetate alone versus in combination with 177Lu-PSMA-617, with or without abirateron…
Rochester, United States Est. completion Dec 30, 2030